StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.
OpGen Stock Up 4.0 %
Shares of OPGN opened at $2.10 on Friday. OpGen has a 1 year low of $1.75 and a 1 year high of $38.40. The company has a 50 day simple moving average of $2.35 and a two-hundred day simple moving average of $3.69.
OpGen (NASDAQ:OPGN – Get Free Report) last announced its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. OpGen had a negative net margin of 1,140.36% and a negative return on equity of 1,827.76%. The firm had revenue of $0.03 million for the quarter.
Hedge Funds Weigh In On OpGen
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Featured Articles
- Five stocks we like better than OpGen
- What is Insider Trading? What You Can Learn from Insider Trading
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Use Stock Screeners to Find Stocks
- MarketBeat Week in Review – 9/16 – 9/20
- Technology Stocks Explained: Here’s What to Know About Tech
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.